Clinico-biochemical study of Infective Hepatitis with Special Reference to Liv.52 Therapy
Dave, D.S., M.D. (Paed.), D.C.H., Reader and Head of the Department of Paediatrics Rajput, V.J., M.D. (Paed.), Lecturer in Paediatrics, and Gupta, M.R., M.B.,B.S., D.C.H., Research Assistant, Department of Paediatrics, G.R. Medical College, Gwalior, M.P., India.
Infective hepatitis is an acute communicable disease caused by a virus characterised clinically by symptoms ranging from slight malaise to severe hepatitis and jaundice, culminating in hepatic coma and death. In India 90 per cent of jaundice is due to infective hepatitis.
There is so far no specific therapy for viral hepatitis. It was considered desirable to ascertain the effects of Liv.52 (The Himalaya Drug Co.) which is a combination of indigenous drugs on infective hepatitis.
Liv.52 contains Capparis spinosa (Kabra), Cichorium intybus (Kasni), Solanum nigrum (Makoi), Cassia occidentalis (Kasondi), Terminalia arjuna (Arjuna), Achillea millefolium (Gandana), Tamarix gallica (Jhau).
The drug Liv.52 has been observed to have experimental and clinical evidence of a powerful hepatic stimulant and choleretic, which markedly increases the functional efficiency of liver. It improves digestion and relieves flatulence and discomfort. It protects the hepatic parenchyma against toxic agents and also has anabolic choleretic, stomachic, diuretic aperient action [Sule et al., (1956), Murkibhavi and Sheth (1957), Sheth et al., (1960), Joglekar et al., (1963), Patel and Sadre (1963), Karandikar et al., (1963), Captain and Syed (1966) and Joglekar and Leevy (1970)].
MATERIAL AND METHODS
The present trial on Liv.52 has been carried out in 30 cases of infective hepatitis while 5 patients served as controls, 27 cases were admitted in the children's medical ward J.A. Group of Hospitals attached to G.R. Medical College, Gwalior, while 8 cases were included from the children's medical outpatient department.
A detailed history of each case was taken regarding past illness, environmental contact and family illness. A thorough physical and clinical examination was done of each case. Laboratory tests included routine Hb, total red blood corpuscles, total and differential white blood corpuscles count, urine for bile salts and bile pigments and specific liver function tests including serum bilirubin, Vandenergh reaction, serum alkaline phosphatase and serum proteins. In 8 cases the liver function tests could not be done.
All the patients were kept on routine supportive treatment like glucose, vitamins, broad-spectrum antibiotics and low fat diet. None of them received corticosteroids.
The 35 cases were divided into two groups:
1. Group A – 30 cases – Liv.52 given in addition to routine supportive treatment.
2. Group B – 5 cases – Liv.52 not given, served as control.
Liv.52 was given in the following schedule: Child below 3 years – 10 to 15 drops, three times a day and children above 3 years, 2 tablets or two teaspoonful Liv.52 syrup t.d.s.
The detailed physical and clinical examination and investigations of each case were repeated weekly to assess improvement excepts in eight cases where assessment of improvement was done by clinical examination in the absence of laboratory investigation.
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Table 3: Showing symptomatology in infective hepatitis | ||||||||
| Symptoms | Group A | Group B | ||||||
| No. of cases (30) | % | No. of cases (5) | % | |||||
Fever |
21 | 70.0% | 4 | 80% | ||||
Anorexia |
14 | 46.7% | 2 | 40% | ||||
Yellowish sclera and urine |
29 | 96.7% | 5 | 100% | ||||
Nausea and vomiting |
8 | 26.7% | ||||||
Constipation |
6 | 20.0% | 1 | 20% | ||||
Diarrhoea |
2 | 6.7% | ||||||
Pain in abdomen |
6 | 20.0% | 1 | 20% | ||||
Irritability |
5 | 16.7% | ||||||
Refference: http://www.himalayahealthcare.com/pdf_files/liv212.pdf
Copyrights © 2009 healthyliver.co.uk